Stock Research for EMITF


Featured Broker: Ally Invest

Get the due diligence for another stock.


EMITF Stock Chart & Research Data

The EMITF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the EMITF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


EMITF Due diligence Resources & Stock Charts

The EMITF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View EMITF Detailed Price Forecast - CNN Money CNN View EMITF Detailed Summary - Google Finance
Yahoo View EMITF Detailed Summary - Yahoo! Finance Zacks View EMITF Stock Research & Analysis -

Stock Analysis

TradeIdeas View EMITF Trends & Analysis - Trade-Ideas Barrons View EMITF Major Holders - Barrons
NASDAQ View EMITF Call Transcripts - NASDAQ Seeking View EMITF Breaking News & Analysis - Seeking Alpha
Spotlight View EMITF Annual Report - OTC Report View EMITF OTC Short Report -
TradeKing View EMITF Fundamentals - TradeKing Charts View EMITF SEC Filings - Bar Chart
WSJ View Historical Prices for EMITF - The WSJ Morningstar View Performance/Total Return for EMITF - Morningstar
MarketWatch View the Analyst Estimates for EMITF - MarketWatch CNBC View the Earnings History for EMITF - CNBC
StockMarketWatch View the EMITF Earnings - StockMarketWatch MacroAxis View EMITF Buy or Sell Recommendations - MacroAxis
Bullish View the EMITF Bullish Patterns - American Bulls Short Pains View EMITF Short Pain Metrics -

Social Media Mentions

StockTwits View EMITF Stock Mentions - StockTwits PennyStocks View EMITF Stock Mentions - PennyStockTweets
Twitter View EMITF Stock Mentions - Twitter Invest Hub View EMITF Investment Forum News - Investor Hub
Yahoo View EMITF Stock Mentions - Yahoo! Message Board Seeking Alpha View EMITF Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for EMITF - Insider Cow View Insider Transactions for EMITF - Insider Cow
CNBC View EMITF Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for EMITF - OTC Markets
Yahoo View Insider Transactions for EMITF - Yahoo! Finance NASDAQ View Institutional Holdings for EMITF - NASDAQ

Stock Charts

FinViz View EMITF Stock Insight & Charts - StockCharts View EMITF Investment Charts -
BarChart View EMITF Stock Overview & Charts - BarChart Trading View View EMITF User Generated Charts - Trading View

Latest Financial News for EMITF

Elbit Imaging Announces Several Steps Intended to Strengthen its Financial Position
Posted on Wednesday July 18, 2018

The Company has entered into a Non-Binding Memorandum of Understanding ("MOU") with the Exigent Capital Group ("Exigent") for the sale of between 11,574,146 ordinary shares of Elbit Medical Technologies Ltd. (" Elbit Medical") (5% of its outstanding share capital) and 115,741,467 ordinary shares of Elbit Medical (50% of its outstanding share capital) (the "Maximum Quantity") for a price per share of NIS 0.96 ($0.26 based on the NIS-US$ representative rate of exchange as of today) ("Per Share Price"). Under the terms of the MOU, Exigent is to purchase 11,574,146 shares of Elbit Medical within 30 days of signing a definitive agreement between the parties (the "Initial Closing").

Elbit Imaging Announces That Gamida Cell Receives Orphan Drug Designation From the Fda for Nicord® as a Treatment for Hematopoietic Stem Cell Transplantation
Posted on Tuesday July 17, 2018

Elbit Imaging Ltd. (“EI” or the “Company”) (TASE, NASDAQ: EMITF) announced today that Gamida Cell Ltd. ("Gamida"), an indirect shareholding of the Company, informed that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for NiCord as a treatment for hematopoietic stem cell transplantation (HSCT). Gamida was previously granted orphan drug designation for NiCord by the FDA as a treatment for several hematologic malignancies.

Elbit Imaging Announces Term Sheet In Respect Of A Plot In Chennai, India
Posted on Thursday July 05, 2018

TEL AVIV, ISRAEL / ACCESSWIRE / July 5, 2018 / Elbit Imaging Ltd. ("EI" or the "Company") (EMITF.TA) (EMITF) announced today, further to its press release dated August 2, 2016 (regarding Elbit Plaza India Real Estate Holdings Limited ("EPI") (a jointly controlled subsidiary in which the Company and its subsidiary, Plaza Centers N.V. ("Plaza") each hold a 50% stake) signing a Joint Development Agreement with a local Indian partner (the "Buyer") relating to its 74.7 acre plot in Chennai, India (the "Plot")) that EPI has signed a term sheet with the Buyer in respect to the sale of EPI's subsidiary ("SPV") that holds the Plot (the "Term Sheet"). Under the terms of the Term Sheet, the Buyer shall have a period of 60 (sixty) days to undertake a due diligence process solely with respect to the SPV, following which definitive agreements for the sale of the SPV, in consideration for INR 110 Crores (approximately €13.8 million, subject to adjustment with respect to the previous amount deposited and the existing cash in the SPV) shall be signed and closing shall take place on the same day.

Elbit Imaging Ltd. Announces Israeli Court Ruling In Regards to VAT Assessments
Posted on Monday July 02, 2018

TEL AVIV, ISRAEL / ACCESSWIRE / July 2, 2018 / Elbit Imaging Ltd. (EMITF.TA) (EMITF) ("Elbit" or the "Company") announced today that an Israeli court issued a decision in a lawsuit brought by the Company against the Israeli Tax Authority relating to VAT assessments issued to the Company and relating to the period from April 2006 to June 2011. In the decision, the court accepted in part the Israeli Tax Authority's position and ruled that the Company should have deducted input tax at rates lower than those actually deducted by the Company. Accordingly, the Company is required to pay the Israeli Tax Authority a payment of approximately NIS 16.5 million (excluding interest and linkage differentials) for the relevant period.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.